SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-042251
Filing Date
2024-04-05
Accepted
2024-04-05 16:05:24
Documents
15
Period of Report
2024-05-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A vktx-20240405.htm   iXBRL DEF 14A 1361571
2 GRAPHIC img254162781_0.jpg GRAPHIC 95484
3 GRAPHIC img254162781_1.jpg GRAPHIC 89721
4 GRAPHIC img254162781_2.jpg GRAPHIC 153619
5 GRAPHIC img254162781_3.jpg GRAPHIC 204679
  Complete submission text file 0000950170-24-042251.txt   3370788

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20240405.xsd EX-101.SCH 36261
18 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20240405_htm.xml XML 149799
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37355 | Film No.: 24826464
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)